Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer

Valeria Panebianco, Maria C. Valerio, Alessandro Giuliani, Martina Pecoraro, Isabella Ceravolo, Giovanni Barchetti, Carlo Catalano, Anwar R. Padhani

Research output: Contribution to journalArticle

Abstract

Background Transrectal ultrasound-guided biopsy (TRUS-Bx) is recommended by the European Urology Association (EAU) as the first diagnostic modality for men at risk of prostate cancer (PCa). Current EAU guidelines reserve the use of multiparametric MRI to target or guide any repeat biopsy (mpMRI-Bx). It remains uncertain if TRUS-Bx is effective as a first strategy in terms of costs, diagnostic performance, time to diagnosis, and triage for individualised therapy. Objective To determine the diagnostic and treatment costs and the effectiveness of pathways incorporating mpMRI-Bx compared to TRUS-Bx in men at high risk of PCa. Design, setting, and participants A cost and time analysis was performed using data from a randomised single-centre study of 1140 patients (prostate-specific antigen >4ng/ml) divided into two groups: 570 patients underwent an initial TRUS-Bx and 570 underwent 3-T mpMRI-Bx. Outcome measurements and statistical analysis Budget analyses were used to compare the diagnostic strategies using reimbursement data from the Italian National Health Security system. Analyses of reimbursable diagnostic and treatment costs were undertaken separately. Histologic outcomes, pathway diagnostic accuracy, therapy choices, and time to diagnosis were compared. Results and limitations The cumulative diagnosis costs were 14.6% greater for the mpMRI-Bx pathway than for the TRUS strategy, and 5.2–6.0% higher for therapy. Diagnostic costs were €228 946 for mpMRI-Bx and €199 750 for TRUS-Bx, and the corresponding therapy costs were €1 912 000 and €1 802 800. The mpMRI-Bx strategy was highly effective in excluding clinically significant disease (Gleason ≥7; sensitivity and negative predictive value both 100%, 95% confidence interval 98–100%). The time to diagnosis was significantly shorter for the mpMRI-Bx (median 4.0 mo interquartile range [IQR] 3–6) than for the TRUS-Bx strategy (median 6 mo, IQR 4–12; p
Original languageEnglish
Pages (from-to)208-214
Number of pages7
JournalEuropean urology oncology
Volume1
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Prostatic Neoplasms
Magnetic Resonance Imaging
Costs and Cost Analysis
Urology
Health Care Costs
Security Measures
Biopsy
Triage
Budgets
Therapeutics
Prostate-Specific Antigen
Cost-Benefit Analysis
Guidelines
Confidence Intervals
Health

Keywords

  • Clinical utility
  • Multiparametric magbetic resonance imaging
  • Prostate cancer
  • Targeted biopsy
  • Cost-effectiveness

Cite this

Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. / Panebianco, Valeria; Valerio, Maria C.; Giuliani, Alessandro; Pecoraro, Martina; Ceravolo, Isabella; Barchetti, Giovanni; Catalano, Carlo; Padhani, Anwar R.

In: European urology oncology, Vol. 1, No. 3, 2018, p. 208-214.

Research output: Contribution to journalArticle

Panebianco, Valeria ; Valerio, Maria C. ; Giuliani, Alessandro ; Pecoraro, Martina ; Ceravolo, Isabella ; Barchetti, Giovanni ; Catalano, Carlo ; Padhani, Anwar R. / Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. In: European urology oncology. 2018 ; Vol. 1, No. 3. pp. 208-214.
@article{a4aca9b352ec4140b7a7a91c2bc855a6,
title = "Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer",
abstract = "Background Transrectal ultrasound-guided biopsy (TRUS-Bx) is recommended by the European Urology Association (EAU) as the first diagnostic modality for men at risk of prostate cancer (PCa). Current EAU guidelines reserve the use of multiparametric MRI to target or guide any repeat biopsy (mpMRI-Bx). It remains uncertain if TRUS-Bx is effective as a first strategy in terms of costs, diagnostic performance, time to diagnosis, and triage for individualised therapy. Objective To determine the diagnostic and treatment costs and the effectiveness of pathways incorporating mpMRI-Bx compared to TRUS-Bx in men at high risk of PCa. Design, setting, and participants A cost and time analysis was performed using data from a randomised single-centre study of 1140 patients (prostate-specific antigen >4ng/ml) divided into two groups: 570 patients underwent an initial TRUS-Bx and 570 underwent 3-T mpMRI-Bx. Outcome measurements and statistical analysis Budget analyses were used to compare the diagnostic strategies using reimbursement data from the Italian National Health Security system. Analyses of reimbursable diagnostic and treatment costs were undertaken separately. Histologic outcomes, pathway diagnostic accuracy, therapy choices, and time to diagnosis were compared. Results and limitations The cumulative diagnosis costs were 14.6{\%} greater for the mpMRI-Bx pathway than for the TRUS strategy, and 5.2–6.0{\%} higher for therapy. Diagnostic costs were €228 946 for mpMRI-Bx and €199 750 for TRUS-Bx, and the corresponding therapy costs were €1 912 000 and €1 802 800. The mpMRI-Bx strategy was highly effective in excluding clinically significant disease (Gleason ≥7; sensitivity and negative predictive value both 100{\%}, 95{\%} confidence interval 98–100{\%}). The time to diagnosis was significantly shorter for the mpMRI-Bx (median 4.0 mo interquartile range [IQR] 3–6) than for the TRUS-Bx strategy (median 6 mo, IQR 4–12; p",
keywords = "Clinical utility, Multiparametric magbetic resonance imaging, Prostate cancer, Targeted biopsy, Cost-effectiveness",
author = "Valeria Panebianco and Valerio, {Maria C.} and Alessandro Giuliani and Martina Pecoraro and Isabella Ceravolo and Giovanni Barchetti and Carlo Catalano and Padhani, {Anwar R.}",
year = "2018",
doi = "10.1016/j.euo.2018.03.008",
language = "English",
volume = "1",
pages = "208--214",
journal = "European urology oncology",
issn = "2588-9311",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer

AU - Panebianco, Valeria

AU - Valerio, Maria C.

AU - Giuliani, Alessandro

AU - Pecoraro, Martina

AU - Ceravolo, Isabella

AU - Barchetti, Giovanni

AU - Catalano, Carlo

AU - Padhani, Anwar R.

PY - 2018

Y1 - 2018

N2 - Background Transrectal ultrasound-guided biopsy (TRUS-Bx) is recommended by the European Urology Association (EAU) as the first diagnostic modality for men at risk of prostate cancer (PCa). Current EAU guidelines reserve the use of multiparametric MRI to target or guide any repeat biopsy (mpMRI-Bx). It remains uncertain if TRUS-Bx is effective as a first strategy in terms of costs, diagnostic performance, time to diagnosis, and triage for individualised therapy. Objective To determine the diagnostic and treatment costs and the effectiveness of pathways incorporating mpMRI-Bx compared to TRUS-Bx in men at high risk of PCa. Design, setting, and participants A cost and time analysis was performed using data from a randomised single-centre study of 1140 patients (prostate-specific antigen >4ng/ml) divided into two groups: 570 patients underwent an initial TRUS-Bx and 570 underwent 3-T mpMRI-Bx. Outcome measurements and statistical analysis Budget analyses were used to compare the diagnostic strategies using reimbursement data from the Italian National Health Security system. Analyses of reimbursable diagnostic and treatment costs were undertaken separately. Histologic outcomes, pathway diagnostic accuracy, therapy choices, and time to diagnosis were compared. Results and limitations The cumulative diagnosis costs were 14.6% greater for the mpMRI-Bx pathway than for the TRUS strategy, and 5.2–6.0% higher for therapy. Diagnostic costs were €228 946 for mpMRI-Bx and €199 750 for TRUS-Bx, and the corresponding therapy costs were €1 912 000 and €1 802 800. The mpMRI-Bx strategy was highly effective in excluding clinically significant disease (Gleason ≥7; sensitivity and negative predictive value both 100%, 95% confidence interval 98–100%). The time to diagnosis was significantly shorter for the mpMRI-Bx (median 4.0 mo interquartile range [IQR] 3–6) than for the TRUS-Bx strategy (median 6 mo, IQR 4–12; p

AB - Background Transrectal ultrasound-guided biopsy (TRUS-Bx) is recommended by the European Urology Association (EAU) as the first diagnostic modality for men at risk of prostate cancer (PCa). Current EAU guidelines reserve the use of multiparametric MRI to target or guide any repeat biopsy (mpMRI-Bx). It remains uncertain if TRUS-Bx is effective as a first strategy in terms of costs, diagnostic performance, time to diagnosis, and triage for individualised therapy. Objective To determine the diagnostic and treatment costs and the effectiveness of pathways incorporating mpMRI-Bx compared to TRUS-Bx in men at high risk of PCa. Design, setting, and participants A cost and time analysis was performed using data from a randomised single-centre study of 1140 patients (prostate-specific antigen >4ng/ml) divided into two groups: 570 patients underwent an initial TRUS-Bx and 570 underwent 3-T mpMRI-Bx. Outcome measurements and statistical analysis Budget analyses were used to compare the diagnostic strategies using reimbursement data from the Italian National Health Security system. Analyses of reimbursable diagnostic and treatment costs were undertaken separately. Histologic outcomes, pathway diagnostic accuracy, therapy choices, and time to diagnosis were compared. Results and limitations The cumulative diagnosis costs were 14.6% greater for the mpMRI-Bx pathway than for the TRUS strategy, and 5.2–6.0% higher for therapy. Diagnostic costs were €228 946 for mpMRI-Bx and €199 750 for TRUS-Bx, and the corresponding therapy costs were €1 912 000 and €1 802 800. The mpMRI-Bx strategy was highly effective in excluding clinically significant disease (Gleason ≥7; sensitivity and negative predictive value both 100%, 95% confidence interval 98–100%). The time to diagnosis was significantly shorter for the mpMRI-Bx (median 4.0 mo interquartile range [IQR] 3–6) than for the TRUS-Bx strategy (median 6 mo, IQR 4–12; p

KW - Clinical utility

KW - Multiparametric magbetic resonance imaging

KW - Prostate cancer

KW - Targeted biopsy

KW - Cost-effectiveness

U2 - 10.1016/j.euo.2018.03.008

DO - 10.1016/j.euo.2018.03.008

M3 - Article

VL - 1

SP - 208

EP - 214

JO - European urology oncology

JF - European urology oncology

SN - 2588-9311

IS - 3

ER -